ADAC Laboratories saw revenues and net income rise sharply forits third quarter (end-June). The Milpitas, CA, vendor attributedthe growth to several factors, including the addition of revenuesfrom information systems vendor Community Health Computing,
ADAC Laboratories saw revenues and net income rise sharply forits third quarter (end-June). The Milpitas, CA, vendor attributedthe growth to several factors, including the addition of revenuesfrom information systems vendor Community Health Computing, acquiredlast year, and increased sales of both gamma cameras and informationsystems.
For the quarter, ADAC posted sales of $62.4 million, up 37%from revenues of $45.6 million in the third quarter of 1995. ADACCFO Andre Simone said much of the growth was due to higher gammacamera sales related to the company's molecular coincidence detection(MCD) high-energy imaging technique. Gamma camera purchasers wantto acquire ADAC cameras so they can add MCD when it begins shipping,Simone said. ADAC plans to begin shipping the technology on completionof clinical trials designed to validate the technique.
ADAC's revenue increase was also due to the addition of revenuesfrom CHC, which were not included in ADAC's third-quarter resultslast year. ADAC has been successful in growing sales in that businessas well, Simone said.
Net income was another bright spot for ADAC. The company hadnet income of $4.4 million for the quarter, compared with $3.1million in the same period last year.
In other news, ADAC announced that it has been awarded a two-yearcontract as a preferred provider for the Columbia/HCA hospitalchain, joining GE Medical Systems as the only other preferredvendor for gamma cameras.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.